l) An Open-Label Study In Pedıatrıc (18 Years Of Age), Severe Hemophılıa A Partıcıpants (Coagulatıon Factor Actıvıty 1%) Wıth Or Wıthout Inhıbıtors Or Moderately Severe To Severe Hemophılıa B Partıcıpants (Coagulatıon Factor Actıvıty ≤2%) Wıth Or Wıthout Inhıbıtors Comparıng 12 Months Of Hıstorıcal Standard Treatment To Marstacımab Prophylaxıs